Scholar Rock Soars 23% on Positive FDA Meeting for SMA Treatment
Scholar Rock (SRRK) shares jump 23% after constructive FDA meeting regarding apitegromab treatment for spinal muscular atrophy, with 2026 approval anticipated.
/ 913 items
#Healthcare↓
Anavex Faces Setback in European Alzheimer's Drug Approval
Anavex Life Sciences receives negative trend vote from EMA for blarcamesine Alzheimer's treatment but plans re-examination and continues FDA discussions.
Bristol Myers & J&J Halt Key Heart Drug Trial After Weak Results
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Avadel Gets Competing Bid from Lundbeck
Avadel Pharmaceuticals receives unsolicited $23/share offer from Lundbeck, competing with existing $20/share Alkermes deal. Board reviewing superior proposal.
Merck's $9.2B Cidara Takeover: Big Pharma's Fight for Flu Innovation
Merck wins bidding war for Cidara Therapeutics at $9.2B, more than double its market value, securing groundbreaking long-acting flu antibody treatment as Big Pharma races for cutting-edge medicines.
Novo Nordisk, Eli Lilly Deny Mangoceuticals Partnership
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.